FindTrial
Sign In

Pharmacoeconomic analysis for cost effectiveness of drugs used for glaucoma

Pharmacoeconomic analysis to determine the relative costeffectiveness of drugs used for primary open angle glaucoma or ocular hypertension - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/11/076826
Enrollment
123
Registered
2024-11-14
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H402- Primary angle-closure glaucoma

Interventions

Control Intervention1: Primary Open angle glaucoma drugs: cost effectiveness analysis

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Age of 18 years and above 2) either gender 3) newly detected case of POAG/OHT 4) Unilateral or bilateral POAG or OHT with IOP more than 21 mm Hg. 5) Patients with bilateral POAG will be treated for both eyes, but the eye with greater decrease in IOP will be considered as the study eye.

Exclusion criteria

Exclusion criteria: 1) Patients with closed anterior chamber angle or acute angle closure glaucoma 2) Any history of intraocular surgery within 6 months of study, 3) Ocular infection or inflammation 4) Established diagnosis of secondary glaucoma 5) Pregnant and lactating females 6) Patients taking any other medication affecting IOP

Design outcomes

Primary

MeasureTime frame
Cost effectiveness analysis Timepoint: Cost effectiveness analysis at 4 weeks—

Secondary

MeasureTime frame
Adverse reactions analysisTimepoint: 4 weeks—

Countries

India

Contacts

Public ContactDr Rima Shah

AIIMS Rajkot

rima_1223@yahoo.co.in9825741010

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026